Radius publishes data on its research in a variety of scientific or medical journals. Below are articles relating to our work in bone health.
April 2023 Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. PharmacoEconomics (2023). Mickaël Hiligsmann, Stuart S Silverman, Andrea J Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis, Jean-Yves Reginster. February 2023 Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics (2023). Nannan Li, Charlotte Beaudart, Jane A. Cauley, Steven W. Ing, Nancy E. Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J. Singer & Mickaël Hiligsmann. Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture. J Am Acad Orthop Surg. 2023;Feb 17. [Epub] Diffenderfer BW, Wang Y, Pearman L, Pyrih N, Wiliams SA. January 2023 Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women with Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend. JBMR. 2023 Jan 1. doi: 10.1002/jbmr.4764. Online ahead of print. Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B. November 2022 An Evaluation of Treatment Patterns for Osteoporosis and Outcomes Following a Fragility Fracture in a Real-world Setting J Orthoped Trauma. 2022. Nov 4. doi: 10.1097/BOT.0000000000002515. Singer AJ, Williams SA, Pearman L, Wang Y, Pyrih N, Jeray K. Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice Proc Natl Acad Sci U S A. 2022 Dec 13;119(50):e2214396119. doi: 10.1073/pnas.2214396119. Epub 2022 Dec 6. Sato T, Andrade CDC, Yoon SH, Zhao Y, Greenlee WJ, Weber PC, Viswanathan U, Kulp J, Brooks DJ, Demay MB, Bouxsein ML, Mitlak B, Lanske B, Wein MN. October 2022 The Efficacy and Safety of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial. 2022 Oct 3. doi: 10.1002/jbmr.4719. Online ahead of print. Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. Sex-Specific Differences in Gsα-Mediated Signaling Downstream of PTH1R Activation by Abaloparatide in Bone JBMR® Plus (WOA), Vol. 00, No. 00, Month 2022, e10695. Swami S, Johnson J, Vecchi LA, Kim MJ, Lanske B, Johnson RW, Wu JY August 2022 Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. J Clin Endocrinol Metab. 2022 Aug 1. [Online ahead of print.] Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T. Abaloparatide Enhances Fusion and Bone Formation in a Rabbit Spinal Arthrodesis Model. Spine (Phila Pa 1976). 2022 Aug 9. [Online ahead of print.] Morse KW, Moore H, Kumagai H, Hahn W, Koo A, Meyers KN, Bouxsein ML, Brooks DJ, Lanske B, Iyer S, Cunningham M. July 2022 Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice. Endocrinology. 2022;163(7). Daley EJ, Yoon SH, Reyes M, Bruce M, Brooks DJ, Bouxsein M, Potts JT, Kronenberg HM, Wein MN, Lanske B, Jüppner H, Gardella TJ. May 2022 Comparative Effectiveness and Cardiovascular Safety of Abaloparatide and Teriparatide in Postmenopausal Women New to Anabolic Therapy: A US Administrative Claims Database Study. Osteoporos Int. 2022 May 7. [Online ahead of print.] Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA. April 2022 Parathyroid Hormone-Related Peptide and Its Analog, Abaloparatide, Attenuate Lethal Myocardial Ischemia-Reperfusion Injury J Clin Med. 2022 Apr 19;11(9):2273. doi: 10.3390/jcm11092273. Wider J, Undyala VVR, Lanske B, Datta NS, Przyklenk K. Outcomes Post Fragility Fracture Among Members of an Integrated Healthcare Organization. Osteoporosis International. 2022;33:783-790. Adams AL, Ryan DS, Li BH, Williams SA, Wang Y, Weiss RJ, Black DM. A Qualitative Study to Assess US Patient Preferences between Bew Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment. Arch Osteoporos. 2022;17(1):57. Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M. February 2022 Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA). JBMR Plus. 2022; e10612. Winzenrieth R, Kostenuik P, Boxberger J, Wang Y, Humbert L. November 2021 Abaloparatide Effects on Corticl Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal Osteoporosis. Journal of Clinical Densitometry. 2021; [Online ahead of print]. Winzenrieth R, Humbert L, Boxberger JL, Weiss RJ, Wang Y, Kostenuik P. September 2021 Development and Validation of a One Year Predictive Model for Secondary Fractures in Osteoporosis. PLoS ONE. 2021;16(9):e0257246. Williams SA, Greenspan SL, Bancroft T, Chastek BJ, Wang Y, Weiss RJ, Pyrih N, Nichols H, Cauley JA. July 2021 Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population. Annals of Pharmacother. 2021;55(7):821-829. Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR May 2021 Comparable initial engagement of intracellular signaling pathways by parathyroid hormone receptor ligands teriparatide, abaloparatide, and long-acting PTH. JBMR Plus. 2021;5(5):e10441. RADIUS-IIS PUBLICATION. Sato T, Verma S, Khatri A, Dean T, Goransson O, Gardella TJ, Wein MN. Gender Disparities in Osteoporosis Screening and Management Among Older Adults. Advances in Therapy. 2021;(38):3872-3887. Ramachandran S, Williams SA, Weiss RJ, Wang Y, Zhang Y, Nsiah I, Bhattacharya K. Risk Factors for Incident Fracture in Older Adults With Type 2 Diabetes: The Framingham Heart Study. Diabetes Care. 2021;44(7):1547-1555. Dufour AB, Kiel DP, Williams SA, Weiss RJ, Samelson EJ. April 2021 Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2021;36(4):644-653. Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH. March 2021 Abaloparatide Treatment Increases Bone Formation, Bone Density and Bone Strength Without Increasing Bone Resorption in a Rat Model of Hindlimb Unloading. Bone. 2021;144:115801. Teguh DA, Nustad JL, Craven AE, Brooks DJ, Arlt H, Hu D, Baron R, Lanske B, Bouxsein ML. February 2021 Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. Clinical Drug Evaluation. 2021;(41):277-285. Miller PD, Troy S, Weiss RJ, Annett M, Schense J, Williams SA, Mitlak B. Abaloparatide Real-World Patient Experience Study. JBMR Plus. 2021;5(3)e10457. Gold DT, Weiss RJ, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA. January 2021 Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide. Bone. 2021;142:115651. TEIJIN SPONSORED PUBLICATION. Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N. Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-based 3D Modeling. Osteoporosis International. 2021;(32):575-583. Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ. December 2020 Effects of Abaloparatide and Teriparatide on Bone Resorption and Bone Formation in Female Mice. Bone Rep. 2020;13:100291. Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, Lanske B, Besschetnova T. November 2020 Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats JOR Spine. 2021;4:e1132. Arlt H, Besschetnova T, Ominsky MS, Fredericks DC, Lanske B Cardiovascular Safety of Abaloparatide in Postmenopausal Women with Osteoporosis: Analysis from the ACTIVE Phase 3 Trial. J Clin Endocrinol Metab. 2020;105(11):3384-3395. Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR. October 2020 Abaloparatide: An Anabolic Treatment to Reduce Fracture Risk in Postmenopausal Women With Osteoporosis. Current Medical Research and Opinion. 2020;36(11):1861-1872. Miller PD, Bilezikian JP, Fitzpatrick LA, Mitlak B, McCloskey EV, Cosman F, Bone HG. Abaloparatide Followed by Alendronate in Women ≥80 Years With Osteoporosis: Post Hoc Analysis of ACTIVExtend. Menopause. 2020;27(10):1137-1142. Greenspan SL, Fitzpatrick LA, Mitlak B, Wang Y, Harvey NC, Deal C, Cosman F, McClung M. September 2020 Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women With Osteoporosis: Results from the ACTIVExtend Phase 3 Trial. Osteoporosis International. 2020:32;55-61. Watts NB, Dore RK, Baim S, Mitlak B, Hattersley G, Wang Y, Rozental TD, LeBoff MS. July 2020 Characterizing Patients Initiating Abaloparatide, Teriparatide, or Denosumab in a Real-World Setting: a US Linked Claims and EMR Database Analysis Osteoporosis International. 2020;31:2413-2424. Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA. June 2020 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture. Clin Ther. 2020;42(6):1099-1107. Saag KG, Williams SA, Wang Y, Weiss RJ, Cauley JA. May 2020 Economic Burden of Osteoporotic Fractures in US Managed Care Enrollees. Am J Manag Care. 2020; 26(5):e142-e149. Williams SA, Chastek B, Sundquist K, Barrera-Sierra S, Leader D, Weiss RJ, Wang Y, Curtis RJ. February 2020 Cost-Effectiveness of Sequential Treatment with Abaloparatide followed by Alendronate vs. Alendronate Monotherapy in Women at Increased Risk of Fracture: a US Payer Perspective. Semin Arthritis Rheum. 2020; 50(3):394-400. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster J-Y. Osteoporotic Fracture Trends in a Population of US Managed Care Enrollees from 2007 to 2017. Osteoporosis International. 2020; 31(7):1299-1304. Lewiecki EM, Chastek B, Sundquist K, Williams SA, Weiss RJ, Wang Y, Fitzpatrick LA, Curtis JR. Abaloparatide in Postmenopausal Women with Osteoporosis and Type 2 Diabetes: A Post-hoc Analysis of the ACTIVE Study. JBMR Plus. 2020; 4(4):e10346. Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick LA, Wang Y, Schwartz AV, Miller PD, Josse RG. December 2019 Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. J Bone Miner Res. 2019; 34(12):2213-2219. Leder BZ, Zapalowski C, Hu MY, Hattersley G, Lane NE, Singer AJ, Dore RK. November 2019 Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed by Alendronate: Results from Phase 3 ACTIVExtend. Bone Reports. 2019; 11;100230. Deal CL, Mitlak BH, Wang Y, Fitzpatrick LA, Miller PD. Effect of Abaloparatide versus Alendronate on Fracture Risk Reduction in Postmenopausal Women with Osteoporosis. J Clin Endocrinol Metab. 2019; 105(3). Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. October 2019 Impact of Fractures on Quality of Life in Patients with Osteoporosis: a US Cross-Sectional Survey. J Drug Assess. 2019; 8(1):175-183. Gold T, Williams SA, Weiss RJ, Wang Y, Watkins C, Carroll J, Middleton C, Silverman S. August 2019 Abaloparatide In Patients with Mild or Moderate Renal Impairment: Results from the ACTIVE Phase 3 Trial. Curr Med Res Opin. 2019; 35(12):2097-2102. Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid induced osteopenia Osteoporos Int (2019) 30:1607-1616 Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B July 2019 Abaloparatide Improves Cortical Geometry and Trabecular Microarchitecture and Increases Vertebral and Femoral Neck Strength in a Rat Model of Male Osteoporosis. BONE. 2019; 124:148-157. Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B. April 2019 Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: a Network Meta-Analysis. Osteoporosis International. 2019; 30(7):1465-1473. Reginster JY, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. March 2019 Abaloparatide Effect on Forearm Bone Mineral Density and Wrist Fracture Risk in Postmenopausal Women with Osteoporosis. Osteoporosis International. 2019; 30(6):1187-1194. Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption Bone 120 (2019) 148–155 Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, G February 2019 Challenges in Osteoporosis Awareness and Management: Results from a Survey of US Postmenopausal Women. Journal of Drug Assessment. 2019; 8(1):25-31. Lewiecki EM, Leader D, Weiss R, Williams SA. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. Journal of Orthopaedic Research. 2019; 37(4):812-820. Lanske B, Chandler H, Pierce A, Brown J, Ominsky M, Kostenuik P, Hattersley G. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Archives of Osteoporosis. 2019;14(1):15. McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA. January 2019 Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Seminars in Arthritis and Rheumatism. 2019; 49(2):184-196. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Bone Turnover Markers to Explain Changes in Lumbar Spine BMD with Abaloparatide and Teriparatide: Results from ACTIVE. Osteoporos Int. 2019; 30(3):667-673. Eastell R, Mitlak B, Wang Y, Hu MY, Fitzpatrick LA, Black DM. October 2018 Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone. 2018;120:137-140. Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C. August 2018 Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Ann Pharmacother. 2018;53(2):134-143. Le QA, Hay JW, Becker R, Wang Y. July 2018 Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018;25:767-771. McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F. June 2018 Characteristics of recurrent fractures. Osteoporosis Int. 2018;29:1747-1757. Kanis JA, Johansson H, Oden A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgstrom F, McCloskey EV. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide Calcif Tissue Int. 2018;103:540-545. Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. May 2018 ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018;103:2949-2957. Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu M-y, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG. December 2017 Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. Calcif Tissue Int. 2018;102:627-633. McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2018;29:685-697. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G. November 2017 Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2018;29:323-328. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D. August 2017 The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. J Bone Miner Res. 2017;32:1625-1631. McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA. June 2017 Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol. 2017;86:356-365. Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G. April 2017 Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319. Moreira C, Fitzpatrick LA, Wang Y, Recker RR. February 2017 Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92:200-210. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone. 2017;95:143-150. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G. January 2017 One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res. 2017;32:24-33. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32:17-23. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. November 2016 Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int. 2016;99:489-499. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. August 2016 Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722-733. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. January 2016 Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157:141-149. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. February 2015 Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100:697-706. Leder BZ, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.